



ASX ANNOUNCEMENT

Rights Issue Offer Closing Date - Reminder

For Immediate Release:

18 May, 2017

Sydney, Australia – Simavita Limited (**Simavita** or the **Company**) (ASX: SVA) wishes to remind Eligible Holders that its current Non-Renounceable Rights Issue Offer (**Offer**), as announced on May 3, 2017, will close at 5pm (AEST) on Monday, 22 May 2017.

The Offer is available for participation on the basis of 1 new CDI at an issue price of \$0.04 for every 7 existing CDI's held by eligible holders on the record date of 8 May 2017.

Eligible holders wishing to accept the Offer must do so prior to 5pm (AEST), Monday, May 22, 2017. Eligible holders also have the opportunity to apply for additional shares in excess of their entitlement.

Lodge Partners acted as Lead Manager, whilst Lodge Corporate Pty Ltd is acting as Underwriter to the Offer. The Offer is partially underwritten to an amount of A\$700,000.

Transaction Timetable*

Event	Date
Closing Date for acceptances under the Offer	5.00pm (AEST) on Monday, 22 May 2017
New CDIs quoted on a deferred settlement basis	Tuesday, 23 May 2017
ASX notified of under subscriptions under the Offer	Thursday, 25 May 2017
Issue of the New CDIs (Deferred settlement trading of New CDIs ends)	Monday, 29 May 2017
Trading of New CDIs expected to commence	Tuesday, 30 May 2017

* The above dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act and the Listing Rules, to extend the Closing Date or to withdraw the Offer at any time without prior notice, in which case all Application Monies will be refunded (without interest) as soon as practicable. Any extension of the Closing Date will have a consequential effect on the issue date of New CDIs.

For further information, please check our website (www.simavita.com) or contact:

Ms Peta Jurd

E: pjurd@simavita.com

T: +61 421 466 653

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing

rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com